B
Bull
Bull · 25%CLSD
$2.29
情境價格
$0.410
-0.111 (-26.96%)收盤時
Loading chart…
- High
- 0.585
- Open
- 0.570
- VWAP
- 0.46
- Vol
- 2.77M
- Mkt Cap
- 95.66M
- Low
- 0.370
- Amount
- 1.26M
- EV/EBITDA, TTM
- 0.00
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Analyst Ratings (6)
Buy
6 Buy
0 Hold
0 Sell
Current: 0.41
最低
—
平均
—
最高
—
Chardan
Neutral
—
2025-07-18
Chardan
2025-07-18
目標價
—
Neutral
H.C. Wainwright
Neutral
—
2025-07-18
H.C. Wainwright
2025-07-18
目標價
—
Neutral
JonesResearch
Hold
—
2025-07-17
JonesResearch
2025-07-17
目標價
—
Hold
Needham
Hold
$3
2025-07-17
Needham
2025-07-17
目標價
$3
Hold
Stifel
Hold
$2
2025-07-17
Stifel
2025-07-17
目標價
$2
Hold
估值指標
The current forward P/E ratio for Clearside Biomedical Inc (CLSD) is -2.05, compared to its 5-year average forward P/E of -7.34.
Alphio AI Price Scenarios for CLSD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
4.511-24BenzingaNasdaq Rises by 350 Points; Enlivex Therapeutics Stock Jumps Significantly
9.011-24NewsfilterClearside Biomedical Files for Chapter 11 Bankruptcy, Seeks Asset Auction
- 9.011-24TipRanks
What’s Causing the Decline in Clearside Biomedical Stock (CLSD) Today?
9.011-24NASDAQ.COMClearside Biomedical Submits Voluntary Chapter 11 Bankruptcy Petition
9.011-24NASDAQ.COMClearside Biomedical Initiates Chapter 11 Bankruptcy Proceedings
CLSD FAQ — answered by Alphio AI
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
6 analysts cover CLSD: 6 rate it Buy, 0 Hold and 0 Sell.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。